非胃肠道感染抗生素使用与IBD flare风险:自控病例系列研究
该研究基于香港全境电子医疗记录,纳入810例曾发生至少1次flare且因胃肠外感染使用至少1疗程抗生素的成人IBD患者,采用自控病例系列设计。结果显示,抗生素使用前1个月、治疗期间及治疗后2周内IBD flare发生率分别升高(IRR 2.85、3.44、4.79),口服及广谱抗生素风险更高,注射剂未见升高。
要点
- 非胃肠道感染使用抗生素与IBD flare短期风险升高相关,治疗后2周内达峰。
- 口服抗生素治疗期间及后2周IRR升高,注射抗生素未见显著升高。
- 广谱抗生素从用药前1个月至后6周IRR高于窄谱抗生素。
核心结论
- 非胃肠道感染使用抗生素与IBD flare短期风险增加相关,注射或窄谱抗生素影响可能相对较小。
研究设计与样本
- 自控病例系列研究,使用香港全境电子医疗记录(2000–2024年)。
- 纳入至少1次flare且因胃肠外感染使用至少1疗程抗生素的成人IBD患者810例。
- 采用条件泊松回归比较预设风险期与基线期的发生率比(IRR)。
主要发现
- 抗生素使用前1个月IBD flare发生率升高(IRR 2.85)。
- 治疗期间IBD flare发生率进一步升高(IRR 3.44)。
- 治疗后2周内IBD flare发生率达峰(IRR 4.79),6个月内回落至基线水平。
- 口服抗生素治疗期间及治疗后2周IRR分别为3.91和3.70,注射抗生素未见升高(交互P值<0.01)。
- 广谱抗生素从用药前1个月至后6周IRR高于窄谱抗生素。
临床怎么用
- 对IBD患者发生非胃肠道感染时,处方抗生素需权衡flare风险,尤其口服和广谱抗生素。
- 可优先考虑注射或窄谱抗生素以降低潜在IBD flare风险。
- 抗生素使用后2周内应加强IBD flare监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Disruption of gut microbiota by antibiotic use has been linked to the development of inflammatory bowel disease (IBD). This study aimed to evaluate the association between antibiotic use for nongastrointestinal (GI) infections and the risk of IBD flare-ups, and to examine whether route of administration, antimicrobial spectrum, and antibiotic class modulate this risk. METHODS: We conducted a self-controlled case series study using territory-wide electronic medical records from Hong Kong. Adults with IBD who experienced at least 1 flare-up and received at least 1 course of antibiotics for infections outside the GI tract between 2000 and 2024 were included, to reduce indication bias related to GI symptoms. Conditional Poisson regression models were used to estimate incidence rate ratios (IRRs) by comparing across predefined risk periods to the baseline period. RESULTS: Among 810 patients, IBD flare incidence was elevated during the month preceding antibiotics (IRR 2.85), increased further during treatment (IRR 3.44), and peaked within 2 weeks after treatment (IRR 4.79), and returned to baseline levels within 6 months, vs baseline. Increased incidences were observed for oral antibiotics during and 2 weeks after treatment (IRRs 3.91 and 3.70), but not for injectable antibiotics (interaction P values <0.01). The IRRs for broad-spectrum antibiotics were higher than those for narrow-spectrum agents from 1 month before to 6 weeks after antibiotic use, vs baseline. DISCUSSION: Antibiotic use for non-GI infections was associated with a short-term increase in IBD flare risk. Injectable or narrow-spectrum antibiotics may have a relatively smaller impact on potential IBD flare-ups.
引用
- Zhang Y, Li X, Fang Q, et al. Association Between Antibiotic Use for Nongastrointestinal Infections and Inflammatory Bowel Disease Flare-Ups: A Self-Controlled Case Series Study. Am J Gastroenterol. 2026. PMID: 41533458. doi:10.14309/ajg.0000000000003920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。